Your browser doesn't support javascript.
loading
End of selection criteria based on sexual orientation: An international symposium on alternatives to donation deferral.
Lewin, Antoine; Goldman, Mindy; Busch, Michael P; Davison, Katy; van de Laar, Thijs; Tiberghien, Pierre; Shinar, Eilat; O'Brien, Sheila F; Lambert, Gilles; Field, Stephen; Hervig, Tor; Tan, Darrell H S; Custer, Brian; Drews, Steven J; Lanteri, Marion C; Klochkov, Denis; Widmer, Eleonora; Domingue, Marie-Pier; Renaud, Christian; Germain, Marc.
  • Lewin A; Medical Affairs and Innovation, Héma-Québec, Montréal and Québec, Quebec, Canada.
  • Goldman M; Donation Policy and Studies, Canadian Blood Services, Ottawa, Ontario, Canada.
  • Busch MP; Vitalant Research Institute, San Francisco, California, USA.
  • Davison K; Department of Laboratory Medicine, University of California in San Francisco, San Francisco, California, USA.
  • van de Laar T; NHS Blood and Transplant/UK Health Security Agency (UKHSA) Epidemiology Unit, UKHSA, London, UK.
  • Tiberghien P; Department of Donor Medicine Research, Sanquin Research, Amsterdam, The Netherlands.
  • Shinar E; Laboratory of Medical Microbiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
  • O'Brien SF; Établissement Français du Sang, La Plaine Saint Denis, France.
  • Lambert G; UMR 1098, Inserm, Établissement Français du Sang, Université de Franche-Comté, Besançon, France.
  • Field S; National Blood Services, Magen David Adom, Tel Aviv, Israel.
  • Hervig T; Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ontario, Canada.
  • Tan DHS; Direction régionale de santé publique - Montréal, Montréal, Québec, Canada.
  • Custer B; Institut national de santé publique du Québec, Montréal, Québec, Canada.
  • Drews SJ; Irish Blood Transfusion Service, Dublin, County Dublin, Ireland.
  • Lanteri MC; Irish Blood Transfusion Service, Dublin, County Dublin, Ireland.
  • Klochkov D; Division of Infectious Diseases, Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada.
  • Widmer E; Vitalant Research Institute, San Francisco, California, USA.
  • Domingue MP; Department of Laboratory Medicine, University of California in San Francisco, San Francisco, California, USA.
  • Renaud C; Donation Policy and Studies, Canadian Blood Services, Edmonton, Alberta, Canada.
  • Germain M; Department of Laboratory Medicine, University of California in San Francisco, San Francisco, California, USA.
Vox Sang ; 119(4): 388-401, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38270352
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Until recently, gay, bisexual and other men who have sex with men (MSM) were deferred from donating blood for 3-12 months since the last male-to-male sexual contact. This MSM deferral has been discontinued by several high-income countries (HIC) that now perform gender-neutral donor selection. MATERIALS AND

METHODS:

An international symposium (held on 20-04-2023) gathered experts from seven HICs to (1) discuss how this paradigm shift might affect the mitigation strategies for transfusion-transmitted infections and (2) address the challenges related to gender-neutral donor selection.

RESULTS:

Most countries employed a similar approach for implementing a gender-neutral donor selection policy key stakeholders were consulted; the transition was bridged by time-limited deferrals; donor compliance was monitored; and questions or remarks on anal sex and the number and/or type of sexual partners were often added. Many countries have now adopted a gender-neutral approach in which questions on pre- and post-exposure prophylaxis for human immunodeficiency virus (HIV) have been added (or retained, when already in place). Other countries used mitigation strategies, such as plasma quarantine or pathogen reduction technologies for plasma and/or platelets.

CONCLUSION:

The experience with gender-neutral donor selection has been largely positive among the countries covered herein and seems to be acceptable to stakeholders, donors and staff. The post-implementation surveillance data collected so far appear reassuring with regards to safety, although longer observation periods are necessary. The putative risks associated with HIV antiretrovirals should be further investigated.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Minorías Sexuales y de Género Límite: Female / Humans / Male Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Minorías Sexuales y de Género Límite: Female / Humans / Male Idioma: En Año: 2024 Tipo del documento: Article